ArticleWorld journal of urology2015
Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer.
Article in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine.Cancers · 2024Review
- Bioinformatics and experimental validation of an AURKA/TPX2 axis as a potential target in esophageal squamous cell carcinoma.Oncology reports · 2023Article
- Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.Bioengineered · 2021Article
- Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance.Cancer medicine · 2021Article
- Tumoral markers in bladder cancer (Review).Experimental and therapeutic medicine · 2021Review
- Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer.Advances in experimental medicine and biology · 2021Article
- Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist.Investigative and clinical urology · 2020Review
- Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression.Antioxidants (Basel, Switzerland) · 2020Article
- Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria.Oncology letters · 2019Article
- Increased AURKA promotes cell proliferation and predicts poor prognosis in bladder cancer.BMC systems biology · 2018Article
- Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette-Guérin on precancerous lesions of bladder in a rat model.International urology and nephrology · 2018Article
- ODF4, MAGEA3, and MAGEB4: Potential Biomarkers in Patients with Transitional Cell CarcinomaIranian biomedical journal · 2018Article
- Urinary Markers in Bladder Cancer: An Update.Frontiers in oncology · 2018Review
- Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes.Technology and health care : official journal of the European Society for Engineering and Medicine · 2018Article
- Identification of key genes associated with bladder cancer using gene expression profiles.Oncology letters · 2018Article
- Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.Scientific reports · 2017Article
- MicroRNA-124-3p affects proliferation, migration and apoptosis of bladder cancer cells through targeting AURKA.Cancer biomarkers : section A of Disease markers · 2017Article
- Histopathology and prognosis of de novo bladder tumors following solid organ transplantation.World journal of urology · 2015Article
- The route to personalized medicine in bladder cancer: where do we stand?Targeted oncology · 2015Review
- Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate urinary Aurora A Kinase (AURKA) mRNA expression as a diagnostic biomarker for urothelial bladder cancer (UBC).
methodsOne hundred and eighty-eight urine samples from patients with UBC (n = 122) and controls with hematuria (n = 66) were investigated. AURKA expression was quantified using real-time PCR and compared with voided urinary cytology. Associations with stage and grade were assessed. The area under curve was used to quantify the predictive accuracy (PA).
resultsThe sensitivity and the specificity of AURKA for UBC were 83.6 and 65.2 %, respectively (PA = 74.4 %). Among those with detectable AURKA, the quantity of expression was similar in cases and controls. Compared with Ta, tumors staged T1 and T2 showed a 9.31-fold and 4.78-fold increased AURKA expression (p = 0.034), respectively. Further, high-grade tumors showed 5.33-fold higher expression levels than low-grade tumors (p = 0.031). AURKA and urinary cytology showed similar overall PA for UBC detection (74.4 vs. 72.1 %, p = 0.588). For low-grade tumors, AURKA was more accurate (72.5 vs. 59.0 %, p = 0.004), while cytology was more accurate for high-grade lesions (76.8 vs. 89.1 %, p = 0.011).
conclusionsIn patients with hematuria, AURKA is associated with the presence and grade of UBC, suggesting a role as diagnostic and prognostic biomarker. As AURKA is more accurate in low-grade tumors but less accurate in high-grade tumors than urinary cytology, both could be complementary in detecting UBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.